The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Jeffery J. Auletta, Amelia M. Bartholomew, Richard Maziarz, Robert J. Deans, Robert H. Miller, Hillard M. Lazarus, Jeffrey A. Cohen

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

Original languageEnglish (US)
Pages (from-to)529-547
Number of pages19
JournalImmunotherapy
Volume4
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Mesenchymal Stromal Cells
Multiple Sclerosis
Cell- and Tissue-Based Therapy
Therapeutics
Translational Medical Research
Demyelinating Diseases
Neurodegenerative Diseases
Wounds and Injuries
Research

Keywords

  • experimental autoimmune encephalomyelitis
  • IFN-γ
  • immunomodulation
  • inflammation
  • mesenchymal stromal cell
  • multiple sclerosis
  • Th17 cell
  • Toll-like receptor
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Auletta, J. J., Bartholomew, A. M., Maziarz, R., Deans, R. J., Miller, R. H., Lazarus, H. M., & Cohen, J. A. (2012). The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy, 4(5), 529-547. https://doi.org/10.2217/imt.12.41

The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. / Auletta, Jeffery J.; Bartholomew, Amelia M.; Maziarz, Richard; Deans, Robert J.; Miller, Robert H.; Lazarus, Hillard M.; Cohen, Jeffrey A.

In: Immunotherapy, Vol. 4, No. 5, 05.2012, p. 529-547.

Research output: Contribution to journalArticle

Auletta, JJ, Bartholomew, AM, Maziarz, R, Deans, RJ, Miller, RH, Lazarus, HM & Cohen, JA 2012, 'The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis', Immunotherapy, vol. 4, no. 5, pp. 529-547. https://doi.org/10.2217/imt.12.41
Auletta, Jeffery J. ; Bartholomew, Amelia M. ; Maziarz, Richard ; Deans, Robert J. ; Miller, Robert H. ; Lazarus, Hillard M. ; Cohen, Jeffrey A. / The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. In: Immunotherapy. 2012 ; Vol. 4, No. 5. pp. 529-547.
@article{cd4bc2d2755040f48fd1a3e8962623e8,
title = "The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis",
abstract = "Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.",
keywords = "experimental autoimmune encephalomyelitis, IFN-γ, immunomodulation, inflammation, mesenchymal stromal cell, multiple sclerosis, Th17 cell, Toll-like receptor, transplantation",
author = "Auletta, {Jeffery J.} and Bartholomew, {Amelia M.} and Richard Maziarz and Deans, {Robert J.} and Miller, {Robert H.} and Lazarus, {Hillard M.} and Cohen, {Jeffrey A.}",
year = "2012",
month = "5",
doi = "10.2217/imt.12.41",
language = "English (US)",
volume = "4",
pages = "529--547",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

AU - Auletta, Jeffery J.

AU - Bartholomew, Amelia M.

AU - Maziarz, Richard

AU - Deans, Robert J.

AU - Miller, Robert H.

AU - Lazarus, Hillard M.

AU - Cohen, Jeffrey A.

PY - 2012/5

Y1 - 2012/5

N2 - Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

AB - Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

KW - experimental autoimmune encephalomyelitis

KW - IFN-γ

KW - immunomodulation

KW - inflammation

KW - mesenchymal stromal cell

KW - multiple sclerosis

KW - Th17 cell

KW - Toll-like receptor

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84861677241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861677241&partnerID=8YFLogxK

U2 - 10.2217/imt.12.41

DO - 10.2217/imt.12.41

M3 - Article

C2 - 22642335

AN - SCOPUS:84861677241

VL - 4

SP - 529

EP - 547

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -